Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
rhTPO for Low/Intermediate-1 Risk MDS with Thrombocytopenia
NCT04324060Phase 3Unknown
- Sponsor
- Peking Union Medical College Hospital
- Start
- Mar 2020
- Primary completion
- Mar 2022
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
A Phase 3 trial of recombinant human thrombopoietin in myelodysplastic syndrome (MDS), sponsored by Peking Union Medical College Hospital. Status: unknown.
02
Drugs
recombinant human thrombopoietin
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT04324060.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04324060.